24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
A better glycemic control is associated with less complications (cardiac diseases, blindness,
etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead
to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than
with a sulphonylurea (glimepiride).